Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 17 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
24 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Hirundo Biosciences from Liège, company number BE0681855065, closed financial year 2025 with a result of € -13.7 million after tax. For that financial year Hirundo Biosciences recorded revenue of € 0 and equity of € -548,240. Compared with financial year 2024, the result moved from € -1.3 million to € -13.7 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
€ -548,240
▼ € 2.3 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -13.7 million
▼ 988 % more loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2 million.
People and assets in 2025
12.2
▲ 9.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.2 million
▲ € 1 million vs 2024
€ 98,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 40,021
▲ 222% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3 million
▲ 131% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 323,879
▲ € 275,953 vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 277,707 | € 0 | ▼ 100% |
| Gross margin | € 290,313 | € 644,133 | € 146,875 | € -2,877,134 | ▼ € 3 million |
| Profit after taxes | € -1,049,080 | € -347,135 | € -1,258,787 | € -13,690,676 | ▼ € 12.4 million |
| Equity | € 3,397,646 | € 3,050,511 | € 1,791,723 | € -548,240 | ▼ € 2.3 million |
| Total debts | € 2,461,070 | € 2,797,799 | € 5,104,745 | € 3,953,682 | ▼ 23% |
| Cash | € 220,608 | € 74,014 | - | - | |
| Retained profit | € -3,652,354 | € -3,999,489 | € -5,258,277 | € -2,016,890 | ▲ € 3.2 million |
| Bank debt | € 1,544,766 | € 1,504,518 | € 0 | € 0 | |
| Balance sheet total | € 5,858,716 | € 5,848,310 | € 6,896,469 | € 3,405,441 | ▼ 51% |
| Employees (FTE) | 2.8 | 2 | 2.7 | 12.2 | ▲ 9.5 |
Key figures of Hirundo Biosciences, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Hirundo Biosciences?
What happened at Hirundo Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- András Kovács Lászlò stepped down as director. NBB
- Istvàn Greiner stepped down as director. NBB
- Péter Turek stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 13.7 million. Source: NBB ↗
- András Kovács Lászlò became a director. NBB
- Istvàn Greiner became a director. NBB
- Péter Turek became a director. NBB
- New establishment in Liège. KBO
In short
From € 1 million loss in 2022 to € 13.7 million loss in 2025.
On average € 54,400 of value added per employee in 2024.
A new publication or filing at Hirundo Biosciences? We notify you, reason included.
Follow Hirundo BiosciencesDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 100% of Hirundo Biosciences France SAS itself.
Directors
According to the 2025 annual accounts
András Kovács Lászlò
Director
since 2025 · until 2030
Istvàn Greiner
Director
since 2024 · until 2030
Péter Turek
Director
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3
4000 Liège
Avenue de l'Hôpital 11
4000 Liège
Active since 28 September 2017
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 24 companies are registered at this address.
All companies at this address →Hyloris Developments
€ 5.1 million revenue · 2025
ONCORADIOMICS
€ 2.4 million gross margin · 2025
DERMAX
€ 1.6 million revenue · 2025
Hyloris
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals
€ 3.8 million revenue · 2025
+19 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0681.855.065
- VAT number
- BE 0681.855.065
- Registered office
- Boulevard de Patience et Beaujonc 3, 4000 Liège
- Names & denominations
- Hirundo Biosciences
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 September 2017
- Peppol
- Active · Active since 3 Dec 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Handel in eigen onroerend goed
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied